Compare ARBEW & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBEW | SENS |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | Israel | United States |
| Employees | 145 | N/A |
| Industry | EDP Services | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 213.2M |
| IPO Year | N/A | 2014 |
| Metric | ARBEW | SENS |
|---|---|---|
| Price | $0.07 | $5.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.38 |
| AVG Volume (30 Days) | 25.5K | ★ 1.2M |
| Earning Date | 03-05-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $768,000.00 | ★ $16,389,000.00 |
| Revenue This Year | N/A | $74.15 |
| Revenue Next Year | N/A | $58.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $0.03 | $0.41 |
| 52 Week High | $0.50 | $8.75 |
| Indicator | ARBEW | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 43.30 |
| Support Level | $0.07 | $5.26 |
| Resistance Level | $0.08 | $5.94 |
| Average True Range (ATR) | 0.01 | 0.49 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 76.72 | 32.29 |
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles, as well as for non-automotive uses. Geographically, the company generates maximum revenue from Sweden, and the rest from China, Hong Kong, the USA, Germany, Israel, and other markets.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.